NTT Named a Leader in the Gartner Magic Quadrant for Network Services, Global Ranked Highest in Gartner Critical Capabilities for Network Services, Global
29.3.2021 11:00:00 EEST | Business Wire | Press release
NTT, a world-leading global technology services provider, today announced it is positioned as a Leader in the March 2021 Gartner ‘Magic Quadrant for Network Services, Global’ report, recognized for both its “Completeness of Vision” and “Ability to Execute.” NTT is also ranked highest in the March 2021 Gartner Critical Capabilities for Network Services, Global report for the Global Network, Intra-Asia/Pacific Network and Intra-EMEA Network Use Cases.
The Gartner Magic Quadrant report states, “Driven by cloud IT service adoption and accelerated by COVID-19, the market for global enterprise network services is undergoing a generational shift in technologies and provider landscape. I&O (Infrastructure & Operations) leaders must adapt their network sourcing approaches to reflect this transformation.”
NTT continues to invest heavily in its global network services portfolio as a transformational driver of innovation for its clients. Known for its exceptional client service and support, NTT has deep expertise in building and managing large, distributed networks. For enterprise CIOs and CDOs pursuing a cloud-first strategy, NTT networking services offer seamless performance for end-users to cloud and SaaS applications, offering a secure, reliable, and enhanced experience whether connecting from home, a branch office, or a large campus.
Masaaki Moribayashi, Senior Executive Vice President for Services for NTT Ltd. said, “Networking is core to delivering agile and impactful solutions for our clients’ rapidly changing business needs. With years of continued investment in our global network services portfolio, it’s a great honor to us to see NTT’s vision, strategy and product portfolio has been well recognized.”
Takeshi Wakita, Senior Vice President for NTT’s Global Network business division, added, “Transformation has always been the foundation of innovation for NTT. We’re incredibly grateful for the hard work of our employees and deep partnership with our clients that allows us to continually raise the bar for our services and offerings.”
For complimentary copies of both reports, click here.
Sources:
1Gartner, Magic Quadrant for Network Services, Global, Neil Rickard, Bjarne Munch, Danellie Young, 2 March 2021.
2Gartner, Critical Capabilities for Network Services, Global, Danellie Young, Bjarne Munch, Lisa Pierce, 3 March 2021
Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About NTT
NTT believes in contributing to society through our business operations by applying technology for good. Our services help clients accelerate their growth and develop new business models.
These services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks – all supported by our deep industry expertise, innovation and solutions.
As a top 5 global technology and business solutions provider, our diverse teams deliver services in over 190 countries and regions. We serve 80%+ of Fortune Global 100 companies and thousands of other clients and communities around the world. For more information on NTT, visit www.global.ntt/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005048/en/
Contact information
H
otwire for NTT Ltd.
Beth Sissons
T: +44 (0)7824 144 109
E: beth.sissons@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
